NCT03499834View on ClinicalTrials.gov

A Study to Evaluate the Safety and Efficacy of Ex Vivo Expanded Autologous Immune Killer Cells (IKC) in Stage IV Non-small Cell Lung Cancer (NSCLC) in Patients Who Failed Chemotherapy or Target Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

December 5, 2017

Primary Completion Date

February 16, 2020

Study Completion Date

February 16, 2020

Conditions
Non-small Cell Lung Cancer (NSCLC) Stage IV
Interventions
BIOLOGICAL

Immune Killer Cells (IKC)

Autologous cells of the immune system. Intravenous Injection (I.V.) frequency: One injection per week, twenty-four injections on-treatment

Trial Locations (2)

Unknown

Taipei Veterans General Hospital, Taipei

Tri Service General Hospital, Taipei

Sponsors
All Listed Sponsors
collaborator

Taipei Veterans General Hospital, Taiwan

OTHER_GOV

collaborator

Tri-Service General Hospital

OTHER

lead

Ivy Life Sciences, Co., Ltd

INDUSTRY

NCT03499834 - A Study to Evaluate the Safety and Efficacy of Ex Vivo Expanded Autologous Immune Killer Cells (IKC) in Stage IV Non-small Cell Lung Cancer (NSCLC) in Patients Who Failed Chemotherapy or Target Therapy | Biotech Hunter | Biotech Hunter